首页> 外文期刊>Urology >Pneumoperitoneum does not potentiate the nephrotoxicity of aminoglycosides in rats.
【24h】

Pneumoperitoneum does not potentiate the nephrotoxicity of aminoglycosides in rats.

机译:气腹不会增强大鼠体内氨基糖苷的肾毒性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Pneumoperitoneum is associated with transient renal dysfunction. To our knowledge, the safety of administering nephrotoxins such as aminoglycosides during pneumoperitoneum has not been studied. Our hypothesis was that pneumoperitoneum potentiates the nephrotoxicity of aminoglycosides. METHODS: From 29 rats we obtained preprocedure 24-hour urine collections. In the pneumoperitoneum group (n = 7), carbon dioxide was insufflated intra-abdominally at 15 mm Hg pressure for 2 hours. In the gentamicin group (n = 7), 10 mg/kg gentamicin was administered intravenously. In the combined pneumoperitoneum/gentamicin group (n = 8), the same dose of gentamicin was administered 10 minutes before pneumoperitoneum. Sham rats (n = 7) received anesthesia only. Urine was collected for the 24 hours after the procedure, and 1 week later blood for creatinine determination and final 24-hour urine collections were obtained. All urine samples were assayed for creatinine and N-acetyl-beta-glucosaminidase (NAG). RESULTS: Only the gentamicin and combined pneumoperitoneum/gentamicin groups presented day 1 values for NAG excretion that were significantly greater than same day sham or paired preprocedure values; the rest of the urinary creatinine and NAG day 1 levels and all the day 7 levels were not significantly different from same day sham or paired preprocedure levels. Day 7 serum creatinine and creatinine clearance did not differ significantly among the groups. CONCLUSIONS: We found that intravenous gentamicin transiently increased urinary excretion of NAG in rats, which resolved within 1 week. Pneumoperitoneum for 2 hours at 15 mm Hg did not increase urinary NAG, either alone or in gentamicin-treated rats. Moreover, our data are sufficient to refute with 95% certainty the possibility that gentamicin plus pneumoperitoneum decreases creatinine clearance more than approximately 60%. These results do not support the hypothesis that pneumoperitoneum potentiates the nephrotoxicity of aminoglycosides.
机译:目的:气腹与短暂性肾功能不全有关。据我们所知,尚未研究在气腹期间使用肾毒素如氨基糖苷类药物的安全性。我们的假设是气腹增强了氨基糖苷的肾毒性。方法:从29只大鼠中,我们获得了术前24小时尿液收集。在气腹组(n = 7)中,在15 mm Hg的压力下向腹腔内通入二氧化碳2小时。在庆大霉素组(n = 7)中,静脉注射10 mg / kg庆大霉素。在气腹/庆大霉素联合治疗组(n = 8)中,在气腹前10分钟给予相同剂量的庆大霉素。假大鼠(n = 7)仅接受麻醉。手术后24小时收集尿液,并于1周后收集血液用于肌酐测定,最后收集24小时尿液。分析所有尿液样本中的肌酐和N-乙酰基-β-氨基葡萄糖苷酶(NAG)。结果:只有庆大霉素和气腹/庆大霉素联合治疗组在第1天的NAG排泄值显着高于当天的假手术或成对的术前值。其余的尿肌酐和NAG第1天的水平以及所有第7天的水平与当天假手术或成对的术前水平没有显着差异。第7天两组之间的血清肌酐和肌酐清除率无显着差异。结论:我们发现静脉注射庆大霉素可暂时增加大鼠NAG的尿排泄,并在1周内消失。单独或在庆大霉素治疗的大鼠中,在15 mm Hg的气腹2小时未增加尿NAG。此外,我们的数据足以以95%的确定性驳斥庆大霉素加气腹对肌酐清除率的降低超过约60%的可能性。这些结果不支持气腹增强氨基糖苷的肾毒性的假说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号